15 October, 2017 by The TZ Newswire Staff Comments Off on New Zealand First Party to continue deliberations on who to back after recent election
New Zealand First Party to continue deliberations on who to back after recent election
Our good friends at Livesquawk reporting news from TVNZ 16 Oct
– NZ First board meeting to determine who the party will back in coalition will continue Tuesday
No further detail.
15 October, 2017 by The TZ Newswire Staff Comments Off on PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
REGULATED INFORMATION
15 October, 2017 by The TZ Newswire Staff Comments Off on OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")
OPENBAARMAKING IN OVEREENSTEMMING MET ARTIKEL 14 VAN DE BELGISCHE WET VAN 2 MEI 2007 BETREFFENDE DE OPENBAARMAKING VAN BELANGRIJKE DEELNEMINGEN (DE "TRANSPARANTIEWET")
GEREGLEMENTEERDE INFORMATIE
15 October, 2017 by The TZ Newswire Staff Comments Off on IBM Universal Payment Solution to Support Central Bank-issued Cryptocurrencies
IBM Universal Payment Solution to Support Central Bank-issued Cryptocurrencies
IBM, KlickEx and Stellar use open-source blockchain technology to cut costs of cross-border payments.
15 October, 2017 by The TZ Newswire Staff Comments Off on ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER
ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER
GHENT, Belgium, 16 October 2017 – Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced the establishment of Ablynx, Inc., its subsidiary in the USA, and the appointment of Mr Daniel Schneider as the General Manager to lead the commercialisation of caplacizumab in North America. Mr Daniel (Dan) Schneider will be based in a US office, to be located on the East Coast. Caplacizumab is the Company’s wholly-owned anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
15 October, 2017 by The TZ Newswire Staff Comments Off on ABLYNX ZET DOCHTERMAATSCHAPPIJ OP IN DE VS EN BENOEMT EEN GENERAL MANAGER
ABLYNX ZET DOCHTERMAATSCHAPPIJ OP IN DE VS EN BENOEMT EEN GENERAL MANAGER
GENT, België, 16 oktober 2017 – Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] berichtte vandaag de oprichting van Ablynx, Inc., haar dochteronderneming in de VS, en de benoeming van Mr Daniel Schneider tot General Manager om de commercialisering van caplacizumab in Noord-Amerika te leiden. Mr Daniel (Dan) Schneider zal werken vanuit een kantoor in de VS, gelegen aan de oostkust.
15 October, 2017 by The TZ Newswire Staff Comments Off on INNATE PHARMA : IPH4102: Résultats finaux de la partie escalade de dose de l’étude de Phase I
INNATE PHARMA : IPH4102: Résultats finaux de la partie escalade de dose de l’étude de Phase I
Présentation des Résultats finaux de l’escalade de dose de l’essai de Phase I évaluant IPH4102 chez des patients atteints de lymphomes T cutanés avancés au congrès de l’EORTC CLTF